Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Buys Oncotech for $45M To Build Dx Chops; First miRNA Test to Launch in 2008

NEW YORK (GenomeWeb News) - Exiqon said today that it will acquire privately held cancer diagnostics maker Oncotech for around $45 million in an all-share deal.
Exiqon, based in Copenhagen, Denmark, said the combined company will market miRNA-based tests that will use Exiqon’s biomarker technology coupled with Oncotech’s cell-based diagnostics infrastructure.
Exiqon said it plans to launch the first of these tests next year.
Exiqon expects Tustin, Calif.-based Oncotech to be the marketing arm for the sale of future diagnostics products based on Exiqon’s LNA technology and miRNA biomarkers.
Oncotech supplies molecular cancer testing services to around 1,200 hospitals, Exiqon said. The deal will become final in January 2008, and should not affect the company’s 2007 financial results.
Oncotech also has a sample bank of human cancer tumors and a CLIA – certified testing laboratory in California.
The combined firm will employ around 200 staffers, Exiqon said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.